Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024)
Rhythm Pharmaceuticals (RYTM) reported Non-Current Deffered Revenue of $109.2 million for Q3 2024, up 4.34% year-over-year from $104.7 million in Q4 2023, and up 0.8% quarter-over-quarter from $108.4 million in Q2 2024.
Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 8 years of Non-Current Deffered Revenue data on file, last reported at $109.2 million in Q3 2024.
- Non-Current Deffered Revenue for Q3 2024 came in at $109.2 million, up 4.34% year-over-year; the trailing twelve-month figure through Sep 2024 was $109.2 million (up 4.34% YoY), and the FY2023 annual result was $106.1 million, up 40.01% from the prior year.
- Non-Current Deffered Revenue rose to $109.2 million in Q3 2024 per RYTM's latest filing, from $108.4 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $109.2 million in Q3 2024 and troughed at $3.0 million in Q1 2020.
- A 4-year average of $85.7 million and a median of $104.7 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue surged 40.01% in 2023, then rose 4.34% in 2024.
- A 4-year view of Non-Current Deffered Revenue shows it stood at $3.0 million in 2020, then soared by 2462.01% to $75.8 million in 2022, then surged by 40.01% to $106.1 million in 2023, then grew by 2.92% to $109.2 million in 2024.
- Business Quant data shows RYTM's Non-Current Deffered Revenue at $109.2 million in Q3 2024, $108.4 million in Q2 2024, and $107.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 109.24 Mn |
| Jun 30, 2024 | 108.37 Mn |
| Mar 31, 2024 | 107.37 Mn |
| Dec 31, 2023 | 106.14 Mn |
| Sep 30, 2023 | 104.70 Mn |
| Jun 30, 2023 | 79.35 Mn |
| Mar 31, 2023 | 77.52 Mn |
| Dec 31, 2022 | 75.81 Mn |
| Mar 31, 2020 | 2.96 Mn |
| Dec 31, 2019 | 3.09 Mn |
| Dec 31, 2018 | 372,000.00 |
| Sep 30, 2018 | 288,000.00 |
| Jun 30, 2018 | 185,000.00 |
| Mar 31, 2018 | 206,000.00 |
| Dec 31, 2017 | 228,000.00 |
| Sep 30, 2017 | 250,000.00 |
| Dec 31, 2016 | 311,000.00 |